Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by Pictet Asset Management SA

Pictet Asset Management SA grew its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating) by 1,894.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,696 shares of the company’s stock after acquiring an additional 142,192 shares during the quarter. Pictet Asset Management SA’s holdings in Maravai LifeSciences were worth $4,253,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MRVI. Zions Bancorporation N.A. acquired a new stake in Maravai LifeSciences during the 1st quarter worth $28,000. SeaCrest Wealth Management LLC purchased a new stake in shares of Maravai LifeSciences in the second quarter valued at about $32,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Maravai LifeSciences by 6,670.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,354 shares of the company’s stock worth $38,000 after buying an additional 1,334 shares during the period. Van ECK Associates Corp purchased a new position in shares of Maravai LifeSciences during the second quarter worth about $81,000. Finally, Point72 Hong Kong Ltd acquired a new position in Maravai LifeSciences in the 1st quarter valued at about $163,000. 51.02% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Up 0.6 %

Shares of NASDAQ MRVI opened at $14.47 on Friday. The stock has a market capitalization of $3.69 billion, a price-to-earnings ratio of 8.08 and a beta of -0.23. Maravai LifeSciences Holdings, Inc. has a 52 week low of $13.40 and a 52 week high of $46.29. The firm has a 50-day moving average price of $19.26 and a 200 day moving average price of $24.69. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62.

Analyst Ratings Changes

MRVI has been the subject of a number of recent research reports. TheStreet cut Maravai LifeSciences from a “c-” rating to a “d+” rating in a research report on Tuesday, July 26th. Robert W. Baird decreased their price target on Maravai LifeSciences from $34.00 to $25.00 in a report on Thursday, November 3rd. Bank of America cut shares of Maravai LifeSciences from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $32.00 to $17.00 in a research note on Thursday, November 3rd. Morgan Stanley reduced their target price on shares of Maravai LifeSciences from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. Finally, KeyCorp cut their price target on shares of Maravai LifeSciences from $35.00 to $28.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.33.

Maravai LifeSciences Profile

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Recommended Stories

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating).

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.